姓名:韩涛
职称:教授、主任医师
导师类型:博士研究生导师/硕士研究生导师
教育经历
1.1995.9–1999.7,首都医科大学,内科学,博士
2.1991.9–1994.7,天津医科大学,内科学,硕士
3.1984.9–1989.7,华中科技大学同济医学院,临床医学,学士
4.2004.9-2005.9, 美国Mayo Clinic, SRF
工作经历
1989.8-1994.7天津市第三中心医院消化(肝病)科医师
1994.7-1999.7天津市第三中心医院消化(肝病)科主治医师
1999.7-2004.11天津市第三中心医院消化(肝病)科副主任医师
2004.11-2021.6天津市第三中心医院消化(肝病)科主任医师
2005.12-2013.9天津市第三中心医院消化(肝病)科科主任
2006.11-2021.6天津市第三中心医院副院长
2021.6-至今天津市人民医院 副院长、主任医师
研究方向
肝脏及消化系疾病的临床和基础研究
承担课题:
1、国家自然科学基金委员会,面上项目,82170630,pH门控琥珀酸分泌激活GPR91的分子网络调控肝再生的机制研究,2022.01-2025.12,主持
2、国家自然科学基金委员会,面上项目,81870429,Tβ4通过下调lncRNA-AIRN抑制肝细胞焦亡缓解急性肝损伤的机制研究,2019-01至2022-12,主持
3、国家科学技术部,“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项,2017ZX10203201007,重症乙型肝炎(肝衰竭)临床治疗新技术研究及新方案推广(子课题),2017/01-2020/12,主持
4、天津市自然科学基金委员会,重点项目,19JCZDJC36700,长链非编码RNAAIRN介导的肝窦内皮细胞毛细血管化在肝纤维化发病过程中的作用及机制研究,2019-04至2022-03,主持
5、国家科技重大专项课题(艾滋病和病毒性肝炎等重大传染病防治),2017ZX10203202-003,卡维地洛延缓乙肝肝硬化抗病毒治疗患者食管静脉曲张进展的临床研究,2021.3-2024.10,主持
学术兼职
中华医学会肝病学分会常委兼任重型肝病与人工肝学组组长、全国疑难及重症肝病攻关协作组副组长.
代表性学术论文
1.Chen T, Shi Z, Zhao Y, Meng X, Zhao S, Zheng L, Han X, Hu Z, Yao Q, Lin H, Du X, Zhang K, Han T, Hong W. LncRNA Airn maintains LSEC differentiation to alleviate liver fibrosis via the KLF2-eNOS-sGC pathway. BMC Med. 2022;20(1):335.
2.Yu Z, Li Y, Shao S, Guo B, Zhang M, Zheng L, Zhang K, Zhou F, Zhang L, Chen C, Jiang W, Hong W, 3.Han T. Protective effect of hepatocyte-enriched lncRNA-Mir122hg by promoting hepatocyte proliferation in acute liver injury. Exp Mol Med. 2022;54(11):2022-2035.
4.Chen Y, Han T, Duan Z; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Clinical application of artificial liver and blood purification: expert consensus recommendations. Hepatol Int. 2023;17(1):4-17.
5. Zhang K, Han X, Zhang Z, Zheng L, Hu Z, Yao Q, Cui H, Shu G, Si M, Li C, Shi Z, Chen T, Han Y, Chang Y, Yao Z*, Han T*, Hong W*. The liver-enriched lnc-LFAR1 promotes liver fibrosis by activating TGFβ and Notch pathways. Nature Communications, 2017;8(1):144.
6.Zhemin Shi, Kun Zhang, Ting Chen, Yu Zhang, Xiaoxiao Du, Yanmian Zhao, Shuai Shao, Lina Zheng, Tao Han*, Wei Hong*. Transcriptional factor ATF3 promotes liver fibrosis via activating hepatic stellate cells. Cell Death Dis. 2020.14;11(12):1066.
7.Kun Zhang, Zhemin Shi, Mengxia Zhang, Xueyi Dong, Lina Zheng, Guantong Li, Xiaohui Han, Zhi Yao*, Tao Han*, Wei Hong*. Silencing lncRNA Lfar1 alleviates the classical activation and pyoptosis of macrophage in hepatic fiborsis. Cell Death Dis, 2020.11(2):132.
8.Kun Zhang, Yawei Han, Zhimei Hu, Zhen Zhang, Shuai Shao, Qingbin Yao, Lina Zheng, Jingzhao Wang, Xiaohui Han, Yu Zhang, Ting Chen, Zhi Yao*, Tao Han*, Wei Hong*. SCARNA10, a nuclear-retained long non-coding RNA, promotes liver fibrosis and serves as a potential biomarker. Theranostics. 2019; 9(12): 3622-3638.
9.Zhenjun Yu, Yu Zhang, Yuhan Li, Feng Zhou, Manman Xu, Shaoli You, Yu Chen, Bing Zhu, Ming Kong, Fangjiao Song, Shaojie Xin, Zhongping Duan, Tao Han*. Development of a Widely Applicable and Simple Prognostic Score for Patients with Acute-on-chronic Liver Failure. J Clin Transl Hepatol,2022.
10.Caiyun Nie, Lei Zhang, Xiaobing Chen, Ying Li, Fushuang Ha, Hua Liu, Tao Han*. Autotaxin: an early warning biomarker for acute-on-chronic liver failure. J Clin Transl Hepatol, 2020; 28;8(3):240-245.
11.Zhenjun Yu, Yu Zhang, Yingying Cao, Manman Xu, Shaoli You, Yu Chen, Bing Zhu, Ming Kong, Fangjiao Song, Shaojie Xin*, Zhongping Duan*, Tao Han*, China Network for Severe Liver Diseases (CNSLD). A dynamic prediction model for prognosis of acute-on-chronic liver failure based on the trend of clinical indicators. Scientific Reports. 2021; 19;11(1):1810.
12.Zhenjun Yu, Yu Zhang, Shuai Shao, Qi Liu, Yuhan Li, Xiaoxiao Du, Kun Zhang, Mengxia Zhang, Haixia Yuan, Qiang Yuan, Tong Liu, Yingtang Gao, Yijun Wang*, Wei Hong*, Tao Han*. Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma. Frontiers in Oncology,2021;11: p.755814.
荣誉和奖励
曾获天津市首批有突出贡献专家、天津医、国之医优秀风范奖、天津市科技奖6项(其中二等奖4项,三等奖2项)、天津市自然科学奖三等奖1项
联系方式
联系邮箱:hantaomd@126.com
联系地址:天津市人民医院,红桥区芥园道190号